Testing the Neuroscience of Guided Learning in Depression

July 7, 2022 updated by: Pearl Chiu, Virginia Polytechnic Institute and State University

Neural Substrates of Reinforcement Learning and Its Training in Major Depression

Major depression is a prevalent and impairing illness. To better understand the basic science and treatment of depression, the investigators study the behavioral and brain processes associated with learning in depression and how potential disruptions in learning may be repaired. Understanding different methods that change learning may lead to novel treatments that contribute to recovery in people with depression.

Study Overview

Detailed Description

Major depressive disorder ranks among the most significant causes of mortality and disability in the world. Recent data from the investigators and others highlight that impairments in reward and loss learning are central to depression, have distinct neural substrates, and improve with successful treatment. Together, these findings suggest an urgent need to delineate the relationships among neural and behavioral learning impairments and depression. Equally important, these insights suggest new targets for treatment such that manipulating the neural and behavioral substrates of learning may facilitate symptom change in depression.

To address these issues, the investigators use functional neuroimaging and a computational psychiatry framework to i) systematically characterize the neural and behavioral substrates that attend reward- and loss- learning in depression and ii) assess the degree to which learning in depression responds to two behavioral methods that target learning in different ways. The investigators test the broad hypotheses that i) that depression may be characterized by distinct neural and behavioral disruptions of learning, and ii) these disruptions and associated symptoms may be ameliorated through different methods of guiding learning. Recent advances in computational psychiatry provide a mechanism-based framework within which to understand the nature and trajectory of potential learning impairments in depression and suggest new ways that disrupted learning and associated symptoms may be improved in depression

Study Type

Interventional

Enrollment (Anticipated)

216

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Virginia
      • Roanoke, Virginia, United States, 24016
        • Virginia Tech Carilion Research Institute

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 55 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • males and females of all ethnicities
  • meet diagnostic criteria for major depression or non-depressed control (assessed by study staff)
  • ages 18-55
  • fluent in English
  • able to see computer display clearly
  • able to provide informed consent
  • able to follow verbal or written instructions
  • for participants who are referred by a clinician, a letter from that clinician indicating that participation in the study does not constitute an elevated medical or behavioral risk to the participant will be requested.

Exclusion Criteria:

  • current pregnancy or menopause
  • claustrophobia
  • MRI contraindications
  • psychotic or bipolar disorder

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: No Training
Guided learning, standard learning: Repeat administration of standard behavioral learning task
Participants will complete repeat sessions of a computer-based learning task, and task performance and symptoms will be assessed.
Experimental: Instructed Statistics
Guided learning, instructed statistics: Repeat administration of behavioral learning task with instructions about task statistics
Participants will complete repeat sessions of a computer-based learning task, and task performance and symptoms will be assessed.
Experimental: Not Instructed Statistics
Guided learning, changing statistics: Repeat administration of behavioral learning task with changing task statistics
Participants will complete repeat sessions of a computer-based learning task, and task performance and symptoms will be assessed.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Task performance
Time Frame: approximately 6 weeks (pre- post- learning task changes and interim time points)
behavioral measures of learning task performance including accuracy, learning rate
approximately 6 weeks (pre- post- learning task changes and interim time points)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Neuroimaging measures
Time Frame: approximately 6 weeks (pre- post- learning task changes and interim time points)
functional MRI during learning task performance
approximately 6 weeks (pre- post- learning task changes and interim time points)
Symptoms
Time Frame: approximately 6 weeks (pre- post- learning task changes and interim time points)
self-report questionnaires and clinician-obtained symptom measures
approximately 6 weeks (pre- post- learning task changes and interim time points)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2016

Primary Completion (Actual)

December 1, 2021

Study Completion (Actual)

December 1, 2021

Study Registration Dates

First Submitted

June 23, 2017

First Submitted That Met QC Criteria

June 26, 2017

First Posted (Actual)

June 29, 2017

Study Record Updates

Last Update Posted (Actual)

July 8, 2022

Last Update Submitted That Met QC Criteria

July 7, 2022

Last Verified

July 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • MDDLEARNING
  • R01MH106756 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Yes

IPD Plan Description

following study completion, de-identified data will be made available to approved researchers and may be requested from the principal investigator

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Major Depressive Disorder

Clinical Trials on Standard Learning

3
Subscribe